MARATTO

review · Science Translational Medicine

The translational gap for gene therapies in low- and middle-income countries

202434 citationsOpen accessUniversity of the Witwatersrand

In plain language

The abstract on record is too brief for a reliable plain-language summary, so none has been generated.

Abstract

Gene therapies are designed to address the root cause of disease. As scientific understanding of disease prevention, diagnosis, and treatment improves in tandem with technological innovation, gene therapies have the potential to become safe and effective treatment options for a wide range of genetic and nongenetic diseases. However, as the medical scope of gene therapies expands, consideration must be given to those who will benefit and what proactive steps must be taken to widen development and access potential, particularly in regions carrying a high disease burden.

Research topics

  • CRISPR and Genetic Engineering
  • CAR-T cell therapy research
  • Biotechnology and Related Fields

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.1126/scitranslmed.adn1902

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.